Cefiderocol is a new parenteral siderophore cephalosporin antibiotic with unique structural features that exploit the way Gram-negative bacteria acquire iron which is necessary for growth. It binds to free iron, and is actively transported across the outer membrane with the iron. This Trojan Horse” strategy allows cefiderocol to enter the periplasmic space where it binds to penicillin-binding proteins (PBPs) and disrupts cell wall synthesis. In addition to improved transportation into bacterial cells, cefiderocol is highly stable to a variety of beta-lactamases.”

Shionogi press release, October 27, 2016